Sopharmaceutical Holdings is listed in Hong Kong, the actual controlling shareholder is China National Pharmaceutical Group Corporation, which is a state-owned enterprise.
Expanded Information
Sopharmaceuticals Holdings is a core enterprise belonging to China National Pharmaceutical Group Corporation (No. 199 on the Fortune 500), founded in January 2003 and listed in Hong Kong in September 2009 (01099.HK). Over the past decade, the company has grown into a leading distributor and retailer of pharmaceuticals and healthcare products and a leading supply chain service provider in China, with an expanding scale of operations, improving quality of operations and sustained growth in profitability.
Since 2005, it has continuously topped the sales list of China's pharmaceutical commercial enterprises. 2011, it was honored as the first pharmaceutical distribution business in China to exceed 100 billion yuan. 2016, it achieved revenue of 258.388 billion yuan, with sales growth continuously leading the industry average, profit growth significantly exceeding sales growth for three consecutive years, with the lowest expense ratio in history since its listing, and was ranked as one of the top 500 companies in China by the Fortune 500 in 2017. Fortune China 500, ranking 22nd. As of June 2017, the company's registered capital was 2.767 billion yuan, with total assets of 173.504 billion yuan and 56,000 employees.
Sopharmaceutical Holdings currently has 480 subsidiaries (including Sinopharm and Sinopharm Consolidated, two listed companies), with a pharmaceutical distribution and delivery network covering 31 provinces (municipalities and districts) and 214 cities out of 335 cities of prefectural level or above, and has built 4 hub-level, 38 provincial-level, 24 retail and 185 prefectural and municipal-level logistics centers in Beijing, Shanghai, Xi'an and Guangzhou, and has built a "smart logistics" network of 185 logistics centers. It has built "intelligent logistics" + "cold chain brand", providing intelligent pharmaceutical supply chain services for 214,000 customers and famous enterprises.
Sopharmaceuticals Holdings, centered on the core strategy of "Wholesale and Retail Integration", vigorously develops the retail diagnosis and treatment business. Ltd. is the largest pharmaceutical retail operator in China in terms of revenue. Ltd. is the No. 1 online pharmaceutical sales company in China (2016), and has completed its Series A financing of 120 million RMB.
The company has formed a pharmaceutical retail chain network that operates both online and offline, and has stores in major cities across China. Currently*** there are 4,106 retail pharmacies, of which 3,693 are China Grand Pharmacies and 413 retail pharmacies are run by various distribution subsidiaries. The company is actively building its second retail brand, SPS+ Specialty Pharmacy, of which more than 30 have been opened.
Sopharmaceutical Holdings Medical Devices Co., Ltd, a subsidiary of Sinopharm, is an integrated operator of medical devices, which integrates product research and development, sales and distribution, and after-sales service. Focusing on overall hospital services and integrating multiple business models, the company provides customers with one-stop total solutions and diversified value-added services, and is committed to building a holistic and integrated service platform for the medical device supply chain.
Sopharmaceutical Group Chemical Reagent Co., Ltd. under Sinopharm is China's first professional company dealing with chemical reagents and glass instruments, and is a professional manufacturer and distributor of large-scale chemical reagents, laboratory consumables, instruments and equipment, laboratory furniture, etc. The applications of its products cover the fields of biotechnology, environmental testing, drug research and development, educational experiments, etc. It has a wide range of products and services, such as medical devices, medical devices, medical equipment and medical equipment. Our products cover biotechnology, environmental testing, drug research and development, educational experiments and other fields; we own Shanghai famous trademarks such as "Shanghai Test" and "Wokai", and Shanghai famous brand products.
Sopharmaceutical Holdings (China) Financial Leasing Co., Ltd. is a subsidiary of Sinopharm Holdings, which provides a full range of financial services such as investment consulting, financial consulting, management consulting, PPP, asset management, etc., with financial leasing as its core business, and also engages in integrated businesses such as commercial factoring and investment. The company is fully engaged in the field of medical and healthcare industry, with its business covering all aspects of the medical and healthcare industry chain, including production, distribution, retailing, and medical terminals.
Sopharmaceuticals Holdings has long been responsible for the national pharmaceutical reserve and emergency supply tasks, in 2003 "SARS", the 2008 southern snowstorm and Wenchuan earthquake, the 2010 Yushu earthquake, the 2013 Ya'an earthquake, the 2016 Wuhan flood, the 2017 Sichuan Jiuzhaigou earthquake and other critical moments, Sinopharm fulfills the national orders. At the moment, Sinopharm fulfilled the national order, shouldered the social responsibility, and resolutely completed the allocation and distribution of the reserve medicines, which played an important role in safeguarding the people's life safety and social stability.
In the face of the new situation of the global pharmaceutical economy, Sinopharm will stand on a new historical starting point, take the opportunity of deepening the reform of mixed ownership system, take the innovation drive as the engine, through scientific and technological innovation, apply the Internet technology, and focus on the core strategy of "wholesaler-retailer integration" to vigorously carry out the development of devices, cold chain, in-hospital medical services, diagnosis and treatment, pharmaceutical e-commerce, financial services, health management and other innovative value-added businesses, and continuously promote the transformation of the company from a traditional service-oriented enterprise to a technology-based service enterprise, to build an "intelligent pharmaceutical service ecosystem", to become an outstanding global pharmaceutical and health service provider, and to create greater value for human health and a better life. We will continue to create greater value for human health and better life.
Reference: